Romosozumab boosted bone strength in postmenopausal women
As per a research, Romosozumab, a bone-forming agent that inhibits sclerostin, may increase bone strength at the spine and hip in postmenopausal women after 12 months of treatment. It is monoclonal antibody that increases bone formation and decreases resorption than placebo, alendronate, and teriparatide in postmenopausal women with low bone mass in previous study.
Osteoporosis affects many women after menopause as their ability to form new bone cannot counter balance rate at which bone is being removed. This bone loss leads to weakened bones, increasing potential for a break. The investigators performed QCT scans at the lumbar spine (mean of L1 and L2 entire vertebral bodies, excluding posterior processes) and hip and assessed from a subset of women participants confirmed the BMD gains with one year of treatment with romosozumab. Romosozumab produced better results than teriparatide. A significant increase in integral volumetric BMD at lumbar spine and total hip from baseline than placebo and teriparatide was found.
The findings at Trabecular hip vBMD were even greater, with an improvement of 10.8% for romosozumab than 4.2% for teriparatide, but for cortical vBMD were similar. However, cortical BMC gains were larger with romosozumab than teriparatide at both the spine and hip.
Results indicated that romosozumab increased bone strength from baseline at month 12 in spine. That was significantly greater than for teriparatide and placebo. The strengthening effect was due to contributions from both cortical and trabecular compartments and these may provide patients with rapid and large increases in bone strength at both the hip and spine.